Put Concerns About Ranitidine and Drug Safety in Perspective
November 2019
Headlines about a probable carcinogen in some Rx and OTC ranitidine products will raise questions about the safety of generic and brand meds.
The buzz is about N-nitrosodimethylamine (NDMA)...the impurity that first sparked recalls of irbesartan, losartan, and valsartan.
Now FDA is investigating how much NDMA is in ranitidine...whether it poses any risk...and the source. In fact, one independent analysis used high temps to test ranitidine...and the test itself generated NDMA.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote